Recent Updates
Recently added Catalysts
ALGS Positive Sentiment

Synergistic fat mass loss in diet-induced obese mice when thyroid hormone receptor-β agonist ALG-055009 was administered in combination with incretin receptor agonists

Saturday, May 30, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: The study highlights the synergistic effects of the thyroid hormone receptor-β agonist ALG-055009 when combined with incretin receptor agonists in promoting fat mass loss in diet-induced obese mice. This combination therapy could represent a novel approach to treating obesity. The findings suggest a promising avenue for further research and potential clinical applications.
Price reaction · baseline $5.7 (2026-05-29 close) · clean, no other ALGS news in the window
day 0 close
-6.1%
day 1 · peak
-7.9%
day 3
-6.3%

Market Sentiment Analysis

POSITIVE FACTORS

  • Combination therapy shows promise for fat mass loss.
  • Potential new treatment for diet-induced obesity.
  • Utilizes thyroid hormone receptor-β agonist effectively.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+153%
120-day peak, hindsight
Typical move
6.1%
average across 6 past catalysts
Cash runway
~3 mo
High dilution risk
Lead asset
ALG-055009
Phase 2 · NASH

Full Press Release Details

• About Overview Management Board of Directors
• Science Pipeline Posters & Presentations
• Patients Chronic HBV Infection MASH Clinical Trials Expanded Access Policy
• News & Media Press Releases Presentations & Events
• Investors Overview Stock Stock Quote & Chart Analyst Coverage News & Events News Releases Investor Calendar Financials SEC Filings Quarterly Results Governance Governance Highlights Committee Composition Resources Investor FAQs Email Alerts Contact IR
• Careers
• Overview
• Management
• Board of Directors
• Pipeline
• Posters & Presentations
• Chronic HBV Infection
• MASH
• Clinical Trials
• Expanded Access Policy
• Press Releases
• Presentations & Events
• Overview
• Stock Stock Quote & Chart Analyst Coverage
• News & Events News Releases Investor Calendar
• Financials SEC Filings Quarterly Results
• Governance Governance Highlights Committee Composition
• Resources Investor FAQs Email Alerts Contact IR
• Stock Quote & Chart
• Analyst Coverage
• News Releases
• Investor Calendar
• SEC Filings
• Quarterly Results
• Governance Highlights
• Committee Composition
• Investor FAQs
• Email Alerts
• Contact IR

Frequently Asked Questions

What is ALG-055009?

ALG-055009 is a thyroid hormone receptor-β agonist studied for its effects on fat mass loss.

How does ALG-055009 work with incretin agonists?

The combination of ALG-055009 with incretin receptor agonists shows synergistic effects in promoting fat loss.

What type of mice were used in the study?

The study was conducted using diet-induced obese mice to evaluate the treatment's efficacy.

What is the significance of this research?

This research may lead to new treatment options for obesity by utilizing combination therapies.

ShareAdd on Google
Tags: ALGS Viatris Investor Conferences Healthcare ALG-055009 thyroid hormone incretin receptor obesity diet-induced
Last updated: May 30, 2026

Biotech snapshot

Cash runway
$30M liquidity · $8M/mo burn
~3 mo
High dilution risk
Lead asset
ALG-055009Phase 2
NASH →

Catalyst track record

+153%
best trade around ALGS's most recent catalyst

Peak hindsight return over a 120-day window, across 6 tracked FDA/PDUFA catalysts for ALGS.

See every catalyst's timing & PoA →